{"id":2014,"date":"2017-12-31T00:00:19","date_gmt":"2017-12-30T17:00:19","guid":{"rendered":"https:\/\/www.hivnat.org\/en\/?p=2014"},"modified":"2022-03-30T10:05:27","modified_gmt":"2022-03-30T03:05:27","slug":"a-phase-iii-multicenter-double-blind-randomized-active-comparator-controlled-clinical-trial-to-evaluate-the-safety-and-efficacy-of-reformulated-raltegravir-1200-mg-once-daily-versus-raltegravir-400","status":"publish","type":"post","link":"https:\/\/www.hivnat.org\/en\/studies\/2014\/","title":{"rendered":"A phase 3 multicenter, double-blind, randomized, active comparator-controlled clinical trial to evaluate the safety and efficacy of reformulated Raltegravir 1200 mg once daily versus Raltegravir 400 mg twice daily, each in combination with TRUVADA\u2122, in treatment-na\u00efve HIV-1 infected subjects"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">This study will evaluate the safety and efficacy of reformulated raltegravir (MK-0518) 1200 mg once daily in combination with TRUVADA\u2122 versus raltegravir 400 mg twice daily in combination with TRUVADA\u2122 in HIV-1 infected, treatment-naive participants. The primary hypothesis being tested is that reformulated raltegravir 1200 mg once-daily is non-inferior to raltegravir 400 mg twice-daily, each in combination therapy with TRUVADA\u2122, as assessed by the proportion of participants achieving HIV-1 ribonucleic acid (RNA) &lt; 40 copies\/mL at Week 48. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>\t\t\t\tThis study will evaluate the safety and efficacy of reformulated raltegravir (MK-0518) 1200 mg once daily in combination with TRUVADA\u2122 versus raltegravir 400 mg twice daily in combination with TRUVADA\u2122 in HIV-1 infected, treatment-naive participants. The primary hypothesis being tested is that reformulated raltegravir 1200 mg once-daily is non-inferior to raltegravir 400 mg twice-daily, each in combination therapy with TRUVADA\u2122, as assessed by the proportion of participants achieving HIV-1 ribonucleic acid (RNA) < 40 copies\/mL at Week 48. \t\t\n<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-2014","post","type-post","status-publish","format-standard","hentry","category-studies"],"_links":{"self":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/2014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/comments?post=2014"}],"version-history":[{"count":1,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/2014\/revisions"}],"predecessor-version":[{"id":3336,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/2014\/revisions\/3336"}],"wp:attachment":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media?parent=2014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/categories?post=2014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/tags?post=2014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}